Connor, Clark & Lunn Investment Management (CC&L)’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14,362	Closed	-$26K	–	1482
2022 Q3	$26K	Buy	+14,362	New	+$41.6K	﹤0.01%	1077
2022 Q1	–	Sell	-28,760	Closed	-$134K	–	1271
2021 Q4	$134K	Buy	28,760 +4,443	+18%	+$27.8K	﹤0.01%	1013
2021 Q3	$207K	Buy	+24,317	New	+$344K	﹤0.01%	942

Other funds holding TCRR

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TCRR Position: Q4 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2022, closing a stake of 14,362 shares — an estimated $26K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TCRR in Q3 2021 and held it in 3 quarters. The position peaked at $207K in Q3 2021. 63 funds tracked by Wall St. Rank hold TCRR as of Q4 2022.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 14,362 TCR2 Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $26K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2021 and held it in 3 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s TCR2 Therapeutics Inc. Common Stock position peaked at $207K in Q3 2021.
63 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2022, filed 10 Feb 2023.